AccentCare turns to AI for readmissions help

Home healthcare provider AccentCare is leveraging AI to track social determinants of health and potentially lower readmissions.

The healthcare provider, which is based in Texas and delivers in-home care and hospice services to more than 240 locations, partnered with clinical AI company Jvion to better understand the risk profile of patients once they’re discharged, Home Health Care News reported. 

“Obviously, something that’s important to us, our patients and our referral partners is readmission risk,” AccentCare CMO Anna Loengard, MD, told Home Health Care News. “And so what’s interesting to me about Jvion is that they will give us a readmission risk score for each patient, with recommended interventions.”

Jvion is an AI-enabled prescriptive analytics company that aims to prevent harm and has continually built up new partnerships with healthcare providers. In 2019, the company became the first member of the Novant Health Institute of Innovation & Artificial Intelligence.

The partnership will help AccentCare understand which patients may be at risk of returning to the hospital––and how best to intervene.

The AI capabilities ensure that AccentCare doesn’t have to utilize front-line staff to track patients by identifying individuals with potential social determinants of health that could put them at risk and flagging those patients for interventions. For example, AccentCare could flag a patient who doesn't’ have transportation access or a nearby pharmacy and potentially enroll the patient in a home delivery service for their medications.

So far, AccentCare is in the beginning stages of rolling out Jvion’s AI technology. 

See the full story at Home Health Care News:

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.